Growth Metrics

Alto Neuroscience (ANRO) Net Cash Flow (2023 - 2026)

Alto Neuroscience has reported Net Cash Flow over the past 4 years, most recently at $87.3 million for Q1 2026.

  • Quarterly results put Net Cash Flow at $87.3 million for Q1 2026, up 1271.26% from a year ago — trailing twelve months through Mar 2026 was $103.0 million (up 330.95% YoY), and the annual figure for FY2025 was $8.3 million, down 90.39%.
  • Net Cash Flow reached $87.3 million in Q1 2026 per ANRO's latest filing, up from $38.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $123.4 million in Q1 2024 and bottomed at -$13.5 million in Q4 2024.
  • Median Net Cash Flow over the past 4 years was -$7.5 million (2025), compared with a mean of $16.6 million.
  • The largest annual shift saw Net Cash Flow tumbled 143.12% in 2024 before it skyrocketed 1271.26% in 2026.
  • Over 4 years, Net Cash Flow stood at $31.3 million in 2023, then crashed by 143.12% to -$13.5 million in 2024, then surged by 386.9% to $38.7 million in 2025, then surged by 125.75% to $87.3 million in 2026.
  • Business Quant data shows Net Cash Flow for ANRO at $87.3 million in Q1 2026, $38.7 million in Q4 2025, and -$9.8 million in Q3 2025.